Revolution Medicines jumps 35% as investors focus on near-term clinical catalysts for daraxonrasib

Revolution Medicines (RVMD) is up 35.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a renewed “catalyst run-up” into major upcoming data disclosures for Revolution’s RAS(ON) inhibitor pipeline, with investors particularly focused on the expected Phase 3 RASolute 302 readout for daraxonrasib in pancreatic cancer. With no single, definitive company announcement clearly explaining a one-day +35% jump, sentiment-driven buying around the timing of conferences and pivotal trial milestones may be playing an outsized role.

Details:

The company has guided to a pivotal readout from RASolute 302 in the first half of 2026, and that event remains the key valuation driver for daraxonrasib in second-line metastatic pancreatic ductal adenocarcinoma.

Revolution also announced multiple presentations at the AACR Annual Meeting (April 17–22, 2026), which can amplify attention on early clinical datasets and combination strategies across the RAS(ON) portfolio.

Recent corporate updates have highlighted ongoing Phase 3 execution and additional Phase 3 program build-out, which can reinforce investor confidence ahead of binary clinical events.

This could also reflect positioning ahead of anticipated trial updates referenced in recent analyst commentary, rather than a single new datapoint released today.

Sources:

Revolution Medicines (Investor Relations), GlobeNewswire, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 23 sales selling 220,265 shares for an estimated $16,635,256.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 5 sales selling 84,430 shares for an estimated $8,370,274.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 5 sales selling 37,450 shares for an estimated $3,578,820.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 5 sales selling 31,275 shares for an estimated $2,534,090.
JEFF CISLINI (General Counsel) has made 0 purchases and 6 sales selling 31,942 shares for an estimated $2,202,346.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 3 sales selling 34,749 shares for an estimated $2,059,927.
LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RVMD Hedge Fund Activity

We have seen 223 institutional investors add shares of $RVMD stock to their portfolio, and 141 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,482,061 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $277,346,158
WELLINGTON MANAGEMENT GROUP LLP removed 2,825,797 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $225,074,731
AVORO CAPITAL ADVISORS LLC added 2,170,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $172,840,500
JPMORGAN CHASE & CO removed 2,076,700 shares (-83.1%) from their portfolio in Q4 2025, for an estimated $165,409,155
UBS GROUP AG added 1,998,972 shares (+183.6%) to their portfolio in Q4 2025, for an estimated $159,218,119
A16Z CAPITAL MANAGEMENT, L.L.C. removed 1,827,424 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $145,554,321
POLAR CAPITAL HOLDINGS PLC added 1,535,686 shares (+321.2%) to their portfolio in Q4 2025, for an estimated $122,317,389

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RVMD Analyst Ratings

Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026
Wolfe Research issued a "Outperform" rating on 11/18/2025
Wedbush issued a "Outperform" rating on 11/06/2025
Needham issued a "Buy" rating on 11/06/2025
HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
JP Morgan issued a "Overweight" rating on 11/06/2025
RBC Capital issued a "Outperform" rating on 11/03/2025

To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 14 analysts offer price targets for $RVMD in the last 6 months, with a median target of $140.0.

Here are some recent targets:

Clara Dong from Jefferies set a target price of $140.0 on 03/16/2026
Ami Fadia from Needham set a target price of $145.0 on 02/26/2026
Eva Fortea Verdejo from Wells Fargo set a target price of $144.0 on 02/26/2026
Kelsey Goodwin from Piper Sandler set a target price of $120.0 on 02/26/2026
Brian Cheng from JP Morgan set a target price of $122.0 on 02/02/2026
Jay Olson from Oppenheimer set a target price of $150.0 on 01/27/2026
Laura Prendergast from Stifel set a target price of $170.0 on 01/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.